ARS Pharmaceuticals, Inc. (SPRY)
ARS Pharmaceuticals, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in San Diego, CA, US. The stock last traded at $5.35, down 2.82% on the session, giving a market capitalisation of $531.3M. On trailing twelve-month figures it carries a trailing P/E of -2.45, a net margin of -184.2%. Its beta of 0.88 implies it has historically moved less than the broad market.
ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial intervention for individuals and their households who are susceptible to life-threatening allergic reactions caused by food, pharmaceuticals, or insect stings. Among its offerings is Neffy, a low-dose version of its intranasal epinephrine nasal spray. Established in 2015, the firm operates out of San Diego, California.
ARS Pharmaceuticals, Inc. is most often compared with the following Healthcare names: